The cathelicidin / antimicrobial peptide story — why the body makes its own antibiotics

The antibiotic resistance crisis is not a projection anymore. It's a present reality. Carbapenem-resistant Enterobacteriaceae, methicillin-resistant Staphylococcus aureus, multidrug-resistant Pseudomonas aeruginosa — these are clinical realities in hospitals on every continent, and the organisms are acquiring resistance faster than new drugs are approved to replace the ones that no longer work. The World Health Organization has listed antibiotic resistance among the greatest threats to global health. The search for alternatives is legitimate and urgent.

What that search has revealed, in part, is that humans — and every other multicellular organism — have been solving this problem for hundreds of millions of years already. Long before penicillin, long before sulfonamides, long before the concept of a pharmaceutical drug existed, every organism with a body surface was producing its own antimicrobial compounds. They are called antimicrobial peptides, and understanding what they are and how they work is one of the more remarkable lessons in pharmacology that evolutionary biology has on offer.

Antimicrobial peptides are short chains of amino acids — typically between twelve and fifty residues — that disrupt or destroy microbial membranes. The human genome encodes dozens of them across several structural families. The defensins, of which there are alpha- and beta-subtypes, are found in neutrophils and in epithelial cells lining the gut, airway, and skin. Histatins are found in saliva. Dermcidin is produced by sweat glands and provides constitutive antimicrobial coverage on skin. The cathelicidins are a family defined by a conserved N-terminal cathelin domain and a variable C-terminal antimicrobial region. Humans produce a single cathelicidin: LL-37.

LL-37 is the processed, active form of the human cathelicidin precursor hCAP18, which is produced primarily by neutrophils, epithelial cells, monocytes, and natural killer cells. The name describes its structure: it begins with two leucines (LL) and is 37 amino acids long. Its mode of action is fundamentally different from most traditional antibiotics. Most antibiotics target specific molecular machinery inside bacteria — cell wall synthesis enzymes, ribosomal subunits, DNA gyrase, folate synthesis pathways. These are specific targets, which is why specific mutations can defeat them. LL-37 targets the bacterial membrane itself. It is cationic — positively charged — and bacterial membranes are anionic — negatively charged. The electrostatic attraction brings LL-37 to the microbial surface. Once there, it inserts into the membrane and disrupts its integrity through mechanisms including pore formation, membrane thinning, and direct lytic activity. The membrane dissolves. The bacterium dies.

The elegance of this mechanism from a resistance perspective is considerable. Bacterial membranes are structurally essential. A bacterium that fundamentally altered the charge composition of its outer membrane to resist LL-37 would likely be nonviable on other grounds. This is not to say resistance to antimicrobial peptides never occurs — it does, and bacteria have evolved countermeasures including proteases that degrade antimicrobial peptides, membrane modifications that reduce accessibility, and efflux pumps — but the barrier to resistance is fundamentally higher than for target-specific antibiotics. LL-37 has been part of the human antimicrobial arsenal for millions of years, and clinical pan-resistance to it has not emerged the way it has for conventional antibiotics.

The antimicrobial spectrum of LL-37 is broad. It is active against gram-positive and gram-negative bacteria, certain fungi, some viruses including influenza and herpes simplex virus, and even some parasites. It's effective against biofilm — the structured community of bacteria embedded in polysaccharide matrix that conventional antibiotics penetrate poorly — with research showing LL-37 can both prevent biofilm formation and disrupt established biofilms. This biofilm activity has particular clinical relevance in conditions including chronic wound infections, periodontal disease, and device-associated infections, where biofilm is the central challenge.

Beyond direct antimicrobial action, LL-37 has immune-modulatory functions that are increasingly understood as equally important. LL-37 is a chemoattractant — it recruits neutrophils, monocytes, and dendritic cells to sites of infection. It modulates TLR4 signaling, the pathway that detects gram-negative bacterial LPS, in complex ways — it can both enhance early detection and help limit excessive inflammatory responses. It induces the production of inflammatory cytokines at low concentrations and has suppressive effects on LPS-induced inflammation at higher concentrations, suggesting a dose-dependent modulatory role. LL-37 promotes wound healing by stimulating keratinocyte migration and proliferation, angiogenesis, and re-epithelialization. It has been found to activate the EGFR pathway in wound healing contexts and to enhance the activity of other immune defense systems. LL-37 is not simply a weapon; it's an immune communication molecule with roles across innate defense, wound repair, and inflammatory regulation.

The conditions where LL-37 deficiency is clinically documented are illuminating. Atopic dermatitis — eczema — is characterized by significantly reduced LL-37 expression in affected skin, which contributes directly to the susceptibility to Staphylococcus aureus colonization and superinfection that worsens atopic dermatitis severity. The barrier dysfunction of eczema skin is thus not only physical but immunological: the skin is producing less of the antimicrobial peptide that would normally prevent colonization. Periodontal disease involves reduced gingival LL-37 expression in the gingival crevicular fluid, contributing to the failure to control the dysbiotic bacterial communities that drive tissue destruction. Chronic non-healing wounds — diabetic foot ulcers, venous leg ulcers — show reduced LL-37 in wound fluid compared to healing wounds; supplementing LL-37 topically has shown promise in accelerating healing in early clinical studies. Respiratory infection susceptibility in conditions including chronic obstructive pulmonary disease involves reduced airway epithelial LL-37 production, which impairs the first-line antimicrobial defense of the respiratory mucosa.

The relationship between vitamin D and LL-37 is important enough to warrant specific attention. The promoter of the CAMP gene — which encodes hCAP18/LL-37 — contains vitamin D response elements. Vitamin D, acting through the vitamin D receptor, directly induces CAMP gene expression, which is why LL-37 production in epithelial cells and macrophages is highly vitamin D-dependent. This is likely part of the mechanism underlying the observed associations between vitamin D deficiency and respiratory infection susceptibility — not just immunological in the classical sense, but antimicrobial peptide-mediated. The finding that respiratory infection incidence is higher at higher latitudes in winter, and that vitamin D supplementation reduces respiratory infection risk in deficient populations, connects mechanistically to this LL-37 pathway.

The therapeutic translation of antimicrobial peptides has been the chronic unfinished story of this field. The scientific promise has been clearly visible for decades. The clinical translation has been excruciating. Magainin Pharmaceuticals — founded in the late 1980s on work from Michael Zasloff's discovery of magainins in the skin of African clawed frogs — developed pexiganan, a synthetic magainin analog, and ran phase III trials for diabetic foot ulcer infections. The FDA declined to approve it in 1999, requesting additional evidence of superiority over standard of care, and the company eventually restructured. Cubist Pharmaceuticals developed daptomycin, a lipopeptide with antimicrobial peptide-like membrane-disruption mechanism, which did achieve FDA approval in 2003 for serious gram-positive infections including MRSA — one of the genuine clinical translation successes in this space. Polyphor developed POL7080, a macrocycle targeting gram-negative bacteria, with promising activity against Pseudomonas; the clinical program has faced the typical barriers. The pattern across most attempted translations has been the combination of high manufacturing cost, stability challenges in biological matrices, difficulty with systemic delivery (antimicrobial peptides tend to be cleared rapidly and are vulnerable to proteolytic degradation), and regulatory benchmarks designed around conventional antibiotic comparators that are difficult for novel-mechanism compounds to meet.

KPV — the alpha-MSH-derived tripeptide lysine-proline-valine — sits at the intersection of antimicrobial peptide research and peptide therapeutics in an interesting way. Alpha-MSH itself has known antimicrobial properties, and KPV, as a fragment that retains some of the parent molecule's activity through melanocortin receptor interactions, has been studied for both anti-inflammatory and antimicrobial properties in gut mucosal contexts. KPV is a research compound without clinical approval; the research examining it for gut inflammatory conditions including inflammatory bowel disease connects through both the anti-inflammatory and antimicrobial mechanisms of its parent peptide.

The topical application space is where antimicrobial peptide research has made the most clinical progress, because topical delivery avoids the stability and distribution challenges of systemic use. Engineered antimicrobial peptides, synthetic analogs, and novel structural variants are in clinical development for wound care, skin infections, and periodontal applications from multiple companies. The biologics landscape for LL-37 specifically includes both recombinant LL-37 and LL-37 derived from cathelicidin precursors in topical formulations; early phase studies have produced encouraging wound healing and antimicrobial data.

What the antimicrobial peptide story teaches about pharmacology is a lesson in humility about the scope of what remains undiscovered. Nature developed a solution to the antibiotic resistance problem that pharmaceutical chemistry spent most of the twentieth century not looking for, because it wasn't looking for it in the right place. The resistance barrier was built into the mechanism from the start — membrane disruption as a strategy is inherently more resistance-resilient than target-specific inhibition — and the immune-modulatory functions were free. Endogenous antimicrobial peptides don't merely kill bacteria; they orchestrate the immune response around the infection in ways that reduce collateral damage and promote healing.

The scientific promise is not in question. The challenge is engineering it into something that can be manufactured at scale, delivered to the right tissue, and protected from the proteolytic environment long enough to work. That challenge has not been fully solved. But the blueprint was never missing. It was always in the skin.